Clinical Trial: Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia

Brief Summary: The purpose of this study is to evaluate the cholesterol lowering effectiveness and safety of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).

Detailed Summary: The duration of treatment is 18 weeks.
Sponsor: Merck Sharp & Dohme Corp.

Current Primary Outcome: Plasma LDL-C vs. fenofibrate for 12 weeks.

Original Primary Outcome:

Current Secondary Outcome: All plasma lipid parameters vs. ezetimibe; all non-LDL lipid parameters vs. fenofibrate; safety and tolerability.

Original Secondary Outcome:

Information By: Merck Sharp & Dohme Corp.

Dates:
Date Received: September 23, 2004
Date Started: December 2002
Date Completion:
Last Updated: February 24, 2017
Last Verified: February 2017